Eiji Oki

List of Publications by Year
in descending order

399 papers	8,664 citations	44069 48 h-index	79698 73 g-index
412 all docs	412 docs citations	412 times ranked	12565 citing authors

#	Article	IF	Citations
1	Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies. Nature Medicine, 2020, 26, 1859-1864.	30.7	209
2	Deregulation of the Akt Pathway in Human Cancer. Current Cancer Drug Targets, 2008, 8, 27-36.	1.6	199
3	Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. Nature Medicine, 2018, 24, 968-977.	30.7	196
4	Activation of PI3K/Akt signaling and hormone resistance in breast cancer. Breast Cancer, 2006, 13, 137-144.	2.9	182
5	Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer. International Journal of Cancer, 2005, 117, 376-380.	5.1	170
6	Akt is frequently activated in HER2/neu-positive breast cancers and associated with poor prognosis among hormone-treated patients. International Journal of Cancer, 2006, 118, 284-289.	5.1	163
7	Activation of Transforming Growth Factor Beta 1 Signaling in Gastric Cancer-associated Fibroblasts Increases Their Motility, via Expression of Rhomboid 5 Homolog 2, and Ability to Induce Invasiveness of Gastric Cancer Cells. Gastroenterology, 2017, 153, 191-204.e16.	1.3	158
8	Advances in esophageal cancer surgery in Japan: An analysis of 1000 consecutive patients treated at a single institute. Surgery, 2008, 143, 499-508.	1.9	155
9	Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 5 Lancet Oncology, The, 2020, 21, 1620-1629.	10.7	152
10	Overexpression of theMTA1 gene in gastrointestinal carcinomas: Correlation with invasion and metastasis. International Journal of Cancer, 1997, 74, 459-463.	5.1	151
11	Alcohol drinking, cigarette smoking, and the development of squamous cell carcinoma of the esophagus: molecular mechanisms of carcinogenesis. International Journal of Clinical Oncology, 2010, 15, 135-144.	2.2	136
12	Integrated Multiregional Analysis Proposing a New Model of Colorectal Cancer Evolution. PLoS Genetics, 2016, 12, e1005778.	3.5	134
13	Sarcopenia is an independent predictor of complications after colorectal cancer surgery. Surgery Today, 2018, 48, 151-157.	1.5	118
14	An Imbalance in TAZ and YAP Expression in Hepatocellular Carcinoma Confers Cancer Stem Cellâ€“like Behaviors Contributing to Disease Progression. Cancer Research, 2015, 75, 4985-4997.	0.9	113
15	CONUT: a novel independent predictive score for colorectal cancer patients undergoing potentially curative resection. International Journal of Colorectal Disease, 2017, 32, 99-106.	2.2	108
16	Surgical treatment of liver metastasis of gastric cancer: a retrospective multicenter cohort study (KSCC1302). Gastric Cancer, 2016, 19, 968-976.	5.3	101
17	Programmed deathâ€ligand 1 expression at tumor invasive front is associated with epithelialâ€mesenchymal transition and poor prognosis in esophageal squamous cell carcinoma. Cancer Science, 2017, 108, 1119-1127.	3.9	100
18	Prognostic Significance of Sarcopenia in Patients with Esophagogastric Junction Cancer or Upper Gastric Cancer. Annals of Surgical Oncology, 2017, 24, 1804-1810.	1.5	91

#	Article	IF	Citations
19	Precise assessment of microsatellite instability using high resolution fluorescent microsatellite analysis. Nucleic Acids Research, 1997, 25, 3415-3420.	14.5	87
20	DNA replication stress and cancer chemotherapy. Cancer Science, 2018, 109, 264-271.	3.9	80
21	Molecular characteristics of colorectal neuroendocrine carcinoma; similarities with adenocarcinoma rather than neuroendocrine tumor. Human Pathology, 2015, 46, 1890-1900.	2.0	79
22	Autophagy Inhibition Dysregulates TBK1 Signaling and Promotes Pancreatic Inflammation. Cancer Immunology Research, 2016, 4, 520-530.	3.4	79
23	Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial): a placebo-controlled, double-blind, randomized phase III study. International Journal of Clinical Oncology, 2015, 20, 767-775.	2.2	78
24	Indocyanine Green Fluorescence Angiography for Quantitative Evaluation of Gastric Tube Perfusion in Patients Undergoing Esophagectomy. Journal of the American College of Surgeons, 2015, 221, e37-e42.	0.5	77
25	Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy. Gastric Cancer, 2017, 20, 175-181.	5.3	77
26	The Long Noncoding RNA CCAT2 Induces Chromosomal Instability Through BOP1-AURKB Signaling. Gastroenterology, 2020, 159, 2146-2162.e33.	1.3	75
27	Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer. JAMA Oncology, 2019, 5, 1574.	7.1	74
28	CIRCULATEâ€Japan: Circulating tumor DNAâ€“guided adaptive platform trials to refine adjuvant therapy for colorectal cancer. Cancer Science, 2021, 112, 2915-2920.	3.9	74
29	Realâ€world data on microsatellite instability status in various unresectable or metastatic solid tumors. Cancer Science, 2021, 112, 1105-1113.	3.9	73
30	The requirement of Mettl3-promoted MyoD mRNA maintenance in proliferative myoblasts for skeletal muscle differentiation. Open Biology, 2017, 7, 170119.	3.6	71
31	Chemosensitivity and Survival in Gastric Cancer Patients with Microsatellite Instability. Annals of Surgical Oncology, 2009, 16, 2510-2515.	1.5	70
32	Mutated gene-specific phenotypes of dinucleotide repeat instability in human colorectal carcinoma cell lines deficient in DNA mismatch repair. Oncogene, 1999, 18, 2143-2147.	5.9	68
33	Genomic landscape of colorectal cancer in Japan: clinical implications of comprehensive genomic sequencing for precision medicine. Genome Medicine, 2016, 8, 136.	8.2	64
34	Epithelial Paradox: Clinical Significance of Coexpression of E-cadherin and Vimentin WithÂRegard to Invasion and Metastasis of BreastÂCancer. Clinical Breast Cancer, 2018, 18, e1003-e1009.	2.4	64
35	A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancer. British Journal of Cancer, 2019, 120, 982-986.	6.4	64
36	Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer. Journal of Clinical Oncology, 2021, 39, 631-641.	1.6	63

#	Article	IF	Citations
37	12-Gene Recurrence Score Assay Stratifies the Recurrence Risk in Stage II/III Colon Cancer With Surgery Alone: The SUNRISE Study. Journal of Clinical Oncology, 2016, 34, 2906-2913.	1.6	62
38	A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2). Gastric Cancer, 2019, 22, 344-354.	5.3	60
39	Actionable gene-based classification toward precision medicine in gastric cancer. Genome Medicine, 2017, 9, 93.	8.2	59
40	Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory toÂtrastuzumab (KSCC1604). European Journal of Cancer, 2018, 105, 41-49.	2.8	58
41	IgG4-related disease of the ileocecal region mimicking malignancy: A case report. International Journal of Surgery Case Reports, 2014, 5, 669-672.	0.6	57
42	Two modes of microsatellite instability in human cancer: differential connection of defective DNA mismatch repair to dinucleotide repeat instability. Nucleic Acids Research, 2005, 33, 1628-1636.	14.5	55
43	High expression of BUBR1 is one of the factors for inducing DNA aneuploidy and progression in gastric cancer. Cancer Science, 2010, 101, 639-645.	3.9	55
44	Discrimination of p53 immunohistochemistryâ€positive tumors by its staining pattern in gastric cancer. Cancer Medicine, 2015, 4, 75-83.	2.8	55
45	Trifluridine Induces p53-Dependent Sustained G2 Phase Arrest with Its Massive Misincorporation into DNA and Few DNA Strand Breaks. Molecular Cancer Therapeutics, 2015, 14, 1004-1013.	4.1	55
46	Clinical significance of programmed cell deathâ€ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability. International Journal of Cancer, 2018, 142, 822-832.	5.1	55
47	Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC): Results from the phase 3 PARADIGM trial.. Journal of Clinical Oncology, 2022, 40, LBA1-LBA1.	1.6	52
48	Targeting Ras-Driven Cancer Cell Survival and Invasion through Selective Inhibition of DOCK1. Cell Reports, 2017, 19, 969-980.	6.4	51
49	The triangulating stapling technique for cervical esophagogastric anastomosis after esophagectomy. Surgery Today, 2009, 39, 201-206.	1.5	49
50	Expression of PD-L1 and HLA Class I in Esophageal Squamous Cell Carcinoma: Prognostic Factors for Patient Outcome. Annals of Surgical Oncology, 2016, 23, 508-515.	1.5	49
51	A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer. European Journal of Cancer, 2018, 91, 86-91.	2.8	48
52	Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin. Journal of Clinical Oncology, 2021, 39, 4009-4019.	1.6	45
53	Câ€reactive protein/albumin ratio is a poor prognostic factor of esophagogastric junction and upper gastric cancer. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 355-363.	2.8	44
54	Mortalin is a prognostic factor of gastric cancer with normal p53 function. Gastric Cancer, 2014, 17, 255-262.	5.3	43

#	Article	IF	Citations
55	Epigenetic Inactivation of BRCA1 Through Promoter Hypermethylation and Its Clinical Importance in Triple-Negative Breast Cancer. Clinical Breast Cancer, 2015, 15, 498-504.	2.4	42
56	The Prognostic Significance of Histone Lysine Demethylase JMJD3/KDM6B in Colorectal Cancer. Annals of Surgical Oncology, 2016, 23, 678-685.	1.5	42
57	Differentiation of early gastric cancer with ulceration and resectable advanced gastric cancer using multiphasic dynamic multidetector CT. European Radiology, 2016, 26, 1330-1337.	4.5	41
58	Laparoscopic Proximal Gastrectomy Maintains Body Weight and Skeletal Muscle Better Than Total Gastrectomy. World Journal of Surgery, 2018, 42, 3270-3276.	1.6	41
59	Prognostic relevance of KRAS and BRAF mutations in Japanese patients with colorectal cancer. International Journal of Clinical Oncology, 2013, 18, 1042-1048.	2.2	40
60	Identification of ARL4C as a Peritoneal Dissemination-Associated Gene and Its Clinical Significance in Gastric Cancer. Annals of Surgical Oncology, 2018, 25, 745-753.	1.5	40
61	p53 Gene mutations in esophageal squamous cell carcinoma and their relevance to etiology and pathogenesis: Results in Japan and comparisons with other countries. Cancer Science, 2007, 98, 1152-1156.	3.9	39
62	Combined Analysis of Concordance between Liquid and Tumor Tissue Biopsies for RAS Mutations in Colorectal Cancer with a Single Metastasis Site: The METABEAM Study. Clinical Cancer Research, 2021, 27, 2515-2522.	7.0	39
63	The Difference in p53 Mutations between Cancers of the Upper and Lower Gastrointestinal Tract. Digestion, 2009, 79, 33-39.	2.3	38
64	The Expression of <i>CCAT2</i>, a Novel Long Noncoding RNA Transcript, and rs6983267 Single-Nucleotide Polymorphism Genotypes in Colorectal Cancers. Oncology, 2017, 92, 48-54.	1.9	38
65	Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial). British Journal of Cancer, 2019, 121, 222-229.	6.4	37
66	Antitumor effects of the antiparasitic agent ivermectin via inhibition of Yes-associated protein 1 expression in gastric cancer. Oncotarget, 2017, 8, 107666-107677.	1.8	37
67	Coexistence of the loss of heterozygosity at the PTEN locus and HER2 overexpression enhances the Akt activity thus leading to a negative progesterone receptor expression in breast carcinoma. Breast Cancer Research and Treatment, 2007, 101, 249-257.	2.5	36
68	Recent advances in treatment for colorectal liver metastasis. Annals of Gastroenterological Surgery, 2018, 2, 167-175.	2.4	36
69	Frequency of Microsatellite Instability inBreast Cancer Determined by High-Resolution Fluorescent Microsatellite Analysis. Oncology, 2000, 59, 44-49.	1.9	35
70	Phase II Study of Docetaxel and S-1 (DS) as Neoadjuvant Chemotherapy for Clinical Stage III Resectable Gastric Cancer. Annals of Surgical Oncology, 2014, 21, 2340-2346.	1.5	35
71	A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study. Clinical Colorectal Cancer, 2018, 17, 147-155.	2.3	35
72	Effect of early oral feeding on length of hospital stay following gastrectomy for gastric cancer: a Japanese multicenter, randomized controlled trial. Surgery Today, 2018, 48, 865-874.	1.5	35

#	Article	IF	Citations
73	Amide proton transfer imaging can predict tumor grade in rectal cancer. Magnetic Resonance Imaging, 2018, 51, 96-103.	1.8	35
74	Postoperative development of sarcopenia is a strong predictor of a poor prognosis in patients with adenocarcinoma of the esophagogastric junction and upper gastric cancer. American Journal of Surgery, 2019, 217, 757-763.	1.8	35
75	Phosphorylation of EB2 by Aurora B and CDK1 ensures mitotic progression and genome stability. Nature Communications, 2016, 7, 11117.	12.8	34
76	Fibroblast growth factor receptor 2 expression, but not its genetic amplification, is associated with tumor growth and worse survival in esophagogastric junction adenocarcinoma. Oncotarget, 2016, 7, 19748-19761.	1.8	34
77	High expression of the Notch ligand Jaggedâ€1 is associated with poor prognosis after surgery for colorectal cancer. Cancer Science, 2016, 107, 1705-1716.	3.9	32
78	Mitotic slippage and the subsequent cell fates after inhibition of Aurora B during tubulin-binding agentâ€“induced mitotic arrest. Scientific Reports, 2017, 7, 16762.	3.3	32
79	Recent Incidence Trend of Surgically Resected Esophagogastric Junction Adenocarcinoma and Microsatellite Instability Status in Japanese Patients. Digestion, 2019, 99, 6-13.	2.3	32
80	Survival Outcomes of Two Phase 2 Studies of Adjuvant Chemotherapy with S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Patients with Gastric Cancer After D2 Gastrectomy. Annals of Surgical Oncology, 2019, 26, 465-472.	1.5	32
81	Impact of Expression of Vimentin and Axl in Breast Cancer. Clinical Breast Cancer, 2016, 16, 520-526.e2.	2.4	31
82	Incidence of Venous Thromboembolism Following Laparoscopic Surgery for Gastrointestinal Cancer: A Singleâ€Center, Prospective Cohort Study. World Journal of Surgery, 2016, 40, 309-314.	1.6	31
83	Protein Expression of Programmed Death 1 Ligand 1 and HER2 in Gastric Carcinoma. Oncology, 2017, 93, 387-394.	1.9	31
84	Prognostic value of BRAF V600E mutation and microsatellite instability in Japanese patients with sporadic colorectal cancer. Journal of Cancer Research and Clinical Oncology, 2017, 143, 151-160.	2.5	30
85	Phase <scp>II</scp> trial of aflibercept with <scp>FOLFIRI</scp> as a secondâ€line treatment for Japanese patients with metastatic colorectal cancer. Cancer Science, 2019, 110, 1032-1043.	3.9	30
86	Prognostic impact of MutT homologâ€1 expression on esophageal squamous cell carcinoma. Cancer Medicine, 2017, 6, 258-266.	2.8	29
87	Effects of Metastatic Sites on Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer. JCO Precision Oncology, 2022, 6, e2100535.	3.0	29
88	Amide proton transfer imaging to predict tumor response to neoadjuvant chemotherapy in locally advanced rectal cancer. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 140-146.	2.8	28
89	Skeletal Muscle Loss After Esophagectomy Is an Independent Risk Factor for Patients with Esophageal Cancer. Annals of Surgical Oncology, 2020, 27, 492-498.	1.5	28
90	Phase Ib/II Study of Biweekly TAS-102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study). Oncologist, 2020, 25, e1855-e1863.	3.7	28

#	Article	IF	Citations
91	Contribution of Aurora-A and -B expression to DNA aneuploidy in gastric cancers. Surgery Today, 2014, 44, 454-461.	1.5	27
92	SPINK1 Status in Colorectal Cancer, Impact on Proliferation, and Role in Colitis-Associated Cancer. Molecular Cancer Research, 2015, 13, 1130-1138.	3.4	27
93	The 1,2-Diaminocyclohexane Carrier Ligand in Oxaliplatin Induces p53-Dependent Transcriptional Repression of Factors Involved in Thymidylate Biosynthesis. Molecular Cancer Therapeutics, 2015, 14, 2332-2342.	4.1	27
94	Skeletal muscle loss during systemic chemotherapy for colorectal cancer indicates treatment response: a pooled analysis of a multicenter clinical trial (KSCC 1605-A). International Journal of Clinical Oncology, 2019, 24, 1204-1213.	2.2	27
95	Circulating Tumor DNA Analysis Detects FGFR2 Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer. Clinical Cancer Research, 2021, 27, 5619-5627.	7.0	27
96	Genetic mutual relationship between PTEN and p53 in gastric cancer. Cancer Letters, 2005, 227, 33-38.	7.2	26
97	Clinical aspect and molecular mechanism of DNA aneuploidy in gastric cancers. Journal of Gastroenterology, 2012, 47, 351-358.	5.1	26
98	Technical Improvement of Total Pharyngo-Laryngo-Esophagectomy for Esophageal Cancer and Head and Neck Cancer. Annals of Surgical Oncology, 2014, 21, 1671-1677.	1.5	26
99	Carbohydrate antigen 19â€9 is a useful prognostic marker in esophagogastric junction adenocarcinoma. Cancer Medicine, 2015, 4, 1659-1666.	2.8	26
100	Evaluation of techniques to prevent colorectal anastomotic leakage. Journal of Surgical Research, 2015, 194, 450-457.	1.6	26
101	High ubiquitinâ€specific protease 44 expression induces DNA aneuploidy and provides independent prognostic information in gastric cancer. Cancer Medicine, 2017, 6, 1453-1464.	2.8	26
102	Histopathologic diversity of gastric cancers: Relationship between enhancement pattern on dynamic contrast-enhanced CT and histological type. European Journal of Radiology, 2017, 97, 90-95.	2.6	26
103	Comprehensive genomic sequencing detects important genetic differences between right-sided and left-sided colorectal cancer. Oncotarget, 2017, 8, 93567-93579.	1.8	26
104	Comparison of Inflammation-Based Prognostic Scores Associated with the Prognostic Impact of Adenocarcinoma of Esophagogastric Junction and Upper Gastric Cancer. Annals of Surgical Oncology, 2021, 28, 2059-2067.	1.5	26
105	Impact of loss of heterozygosity of encoding phosphate and tensin homolog on the prognosis of gastric cancer. Journal of Gastroenterology and Hepatology (Australia), 2006, 21, 814-818.	2.8	25
106	Progression from laparoscopic-assisted to totally laparoscopic distal gastrectomy: comparison of circular stapler (i-DST) and linear stapler (BBT) for intracorporeal anastomosis. Surgical Endoscopy and Other Interventional Techniques, 2013, 27, 325-332.	2.4	25
107	Neoadjuvant Chemoradiotherapy for Patients with cT3/Nearly T4 Esophageal Cancer: Is Sarcopenia Correlated with Postoperative Complications and Prognosis?. World Journal of Surgery, 2018, 42, 2894-2901.	1.6	25
108	Esophagogastric junction adenocarcinoma shares characteristics with gastric adenocarcinoma: Literature review and retrospective multicenter cohort study. Annals of Gastroenterological Surgery, 2021, 5, 46-59.	2.4	25

#	Article	IF	Citations
109	Nuclear expression of chemokine receptor CXCR4 indicates poorer prognosis in gastric cancer. Anticancer Research, 2014, 34, 6397-403.	1.1	25
110	The Impact of Obesity on the Use of a Totally Laparoscopic Distal Gastrectomy in Patients with Gastric Cancer. Journal of Gastric Cancer, 2012, 12, 108.	2.5	24
111	Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer. Gastric Cancer, 2021, 24, 780-789.	5.3	24
112	Y-box binding protein YBX1 and its correlated genes as biomarkers for poor outcomes in patients with breast cancer. Oncotarget, 2018, 9, 37216-37228.	1.8	24
113	Endoscopic evaluation of clinical colorectal anastomotic leakage. Journal of Surgical Research, 2015, 193, 126-134.	1.6	23
114	Lysineâ€specific demethylaseâ€1 contributes to malignant behavior by regulation of invasive activity and metabolic shift in esophageal cancer. International Journal of Cancer, 2016, 138, 428-439.	5.1	23
115	Gastric Cancer Patients with High PLK1 Expression and DNA Aneuploidy Correlate with Poor Prognosis. Oncology, 2016, 91, 31-40.	1.9	23
116	The antibodies against 5-bromo-2â€²-deoxyuridine specifically recognize trifluridine incorporated into DNA. Scientific Reports, 2016, 6, 25286.	3.3	23
117	Blood Flow Assessment with Indocyanine Green Fluorescence Angiography for Pedicled Omental Flap on Cervical Esophagogastric Anastomosis after Esophagectomy. Journal of the American College of Surgeons, 2016, 222, e67-e69.	0.5	23
118	Clinical and Genetic Implications of Mutation Burden in Squamous Cell Carcinoma of the Lung. Annals of Surgical Oncology, 2018, 25, 1564-1571.	1.5	23
119	Comprehensive molecular profiling broadens treatment options for breast cancer patients. Cancer Medicine, 2021, 10, 529-539.	2.8	23
120	Histopathological characteristics and artificial intelligence for predicting tumor mutational burden-high colorectal cancer. Journal of Gastroenterology, 2021, 56, 547-559.	5.1	23
121	Impact of Concurrent Genomic Alterations Detected by Comprehensive Genomic Sequencing on Clinical Outcomes in East-Asian Patients with EGFR-Mutated Lung Adenocarcinoma. Scientific Reports, 2018, 8, 1005.	3.3	22
122	CD44v9 is associated with epithelialâ€mesenchymal transition and poor outcomes in esophageal squamous cell carcinoma. Cancer Medicine, 2018, 7, 6258-6268.	2.8	22
123	Multimodal Treatment Strategy for Clinical T3 Thoracic Esophageal Cancer. Annals of Surgical Oncology, 2013, 20, 4267-4273.	1.5	21
124	Cytolytic activity score as a biomarker for antitumor immunity and clinical outcome in patients with gastric cancer. Cancer Medicine, 2021, 10, 3129-3138.	2.8	21
125	Molecular Characteristics of Basaloid Squamous Cell Carcinoma of the Esophagus: Analysis of KRAS, BRAF, and PIK3CA Mutations and LINE-1 Methylation. Annals of Surgical Oncology, 2015, 22, 3659-3665.	1.5	20
126	APOBEC3B is an enzymatic source of molecular alterations in esophageal squamous cell carcinoma. Medical Oncology, 2016, 33, 26.	2.5	20

#	Article	IF	Citations
127	Postoperative C-reactive protein/albumin ratio is a biomarker of risk of recurrence and need for adjuvant chemotherapy for stage III colorectal cancer. International Journal of Clinical Oncology, 2020, 25, 1318-1326.	2.2	20
128	Impact of intra-abdominal absorbable sutures on surgical site infection in gastrointestinal and hepato-biliary-pancreatic surgery: results of a multicenter, randomized, prospective, phase II clinical trial. Surgery Today, 2017, 47, 1060-1071.	1.5	19
129	Gastric hepatoid adenocarcinomas are a genetically heterogenous group; most tumors show chromosomal instability, but MSI tumors do exist. Human Pathology, 2019, 88, 27-38.	2.0	19
130	REMARRY and PURSUIT trials: liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer. BMC Cancer, 2021, 21, 674.	2.6	19
131	Radiomics Texture Analysis for the Identification of Colorectal Liver Metastases Sensitive to First-Line Oxaliplatin-Based Chemotherapy. Annals of Surgical Oncology, 2021, 28, 2975-2985.	1.5	19
132	Diffuse-type gastric cancer: specific enhancement pattern on multiphasic contrast-enhanced computed tomography. Japanese Journal of Radiology, 2017, 35, 289-295.	2.4	18
133	Suppressor microRNA-145 Is Epigenetically Regulated by Promoter Hypermethylation in Esophageal Squamous Cell Carcinoma. Anticancer Research, 2015, 35, 4617-24.	1.1	18
134	Detection of disseminated cancer cells in bone marrow of gastric cancer using real time quantitative reverse transcriptase polymerase chain reaction. Cancer Letters, 2002, 188, 191-198.	7.2	17
135	Preservation of an Aberrant Hepatic Artery Arising from the Left Gastric Artery during Laparoscopic Gastrectomy for Gastric Cancer. Journal of the American College of Surgeons, 2011, 212, e25-e27.	0.5	17
136	Surgical Resection for Esophageal Cancer Synchronously or Metachronously Associated with Head and Neck Cancer. Annals of Surgical Oncology, 2013, 20, 2434-2439.	1.5	17
137	Overexpression of CXCR7 Is a Novel Prognostic Indicator in Gastric Cancer. Digestive Surgery, 2017, 34, 312-318.	1.2	17
138	Expression of APOBEC3B mRNA in Primary Breast Cancer of Japanese Women. PLoS ONE, 2016, 11, e0168090.	2.5	17
139	Correlation of HER2 expression with clinicopathological characteristics and prognosis in resectable gastric cancer. Anticancer Research, 2015, 35, 2441-6.	1.1	17
140	Aberrant hypermethylation of the promoter region of the CHFR gene is rare in primary breast cancer. Breast Cancer Research and Treatment, 2006, 97, 199-203.	2.5	16
141	Phase II Study of Biweekly Docetaxel and S-1 Combination Therapy for Advanced or Recurrent Gastric Cancer. Oncology, 2009, 77, 49-52.	1.9	16
142	Newly Developed Liver-Retraction Method for Laparoscopic Gastric Surgery Using a Silicone Disc: The Î¦-Shaped Technique. Journal of the American College of Surgeons, 2013, 216, e43-e46.	0.5	16
143	Phase II Trial of S-1 and Oxaliplatin Plus Cetuximab for Colorectal Cancer Patients with Initially Unresectable or Not Optimally Resectable Liver Metastases (KSCC1002). Annals of Surgical Oncology, 2015, 22, 1067-1074.	1.5	16
144	Clinicopathologic and Molecular Characteristics of Synchronous Colorectal Carcinoma With Mismatch Repair Deficiency. American Journal of Surgical Pathology, 2018, 42, 172-182.	3.7	16

#	Article	IF	Citations
145	Effect of lateral lymph node dissection for mid and low rectal cancer: An ad-hoc analysis of the ACTS-RC (JFMC35-C1) randomized clinical trial. Surgery, 2019, 165, 586-592.	1.9	16
146	Clinical significance of signal regulatory protein alpha (SIRPÎ±) expression in esophageal squamous cell carcinoma. Cancer Science, 2021, 112, 3018-3028.	3.9	16
147	Liver resectability of advanced liver-limited colorectal liver metastases following mFOLFOX6 with bevacizumab (KSCC0802 Study). Anticancer Research, 2014, 34, 6655-62.	1.1	16
148	Clinical significance of micrometastasis in bone marrow of patients with gastric cancer and its relation to angiogenesis. Gastric Cancer, 1999, 2, 46-51.	5.3	15
149	Neoadjuvant Chemotherapy Versus Chemoradiotherapy for Patients with Esophageal Squamous Cell Carcinoma. Anticancer Research, 2018, 38, 6809-6814.	1.1	15
150	A case of mixed adenoneuroendocrine carcinoma (MANEC) arising in Barrettâ€™s esophagus: literature and review. Surgical Case Reports, 2018, 4, 45.	0.6	15
151	Role of Predictive Value of the Modified Glasgow Prognostic Score for Later-line Chemotherapy in Patients With Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2018, 17, e687-e697.	2.3	15
152	Aberrations of BUBR1 and TP53 gene mutually associated with chromosomal instability in human colorectal cancer. Anticancer Research, 2014, 34, 5421-7.	1.1	15
153	Outcome of esophagojejunostomy during totally laparoscopic total gastrectomy: a single-center retrospective study. Anticancer Research, 2014, 34, 7227-32.	1.1	15
154	Surgical Complications and the Risk Factors of Totally Laparoscopic Distal Gastrectomy. Surgical Laparoscopy, Endoscopy and Percutaneous Techniques, 2011, 21, 146-150.	0.8	14
155	Postoperative Skeletal Muscle Loss Predicts Poor Prognosis of Adenocarcinoma of Upper Stomach and Esophagogastric Junction. World Journal of Surgery, 2019, 43, 1068-1075.	1.6	14
156	Solidâ€type poorly differentiated adenocarcinoma of the stomach: Deficiency of mismatch repair and SWI/SNF complex. Cancer Science, 2020, 111, 1008-1019.	3.9	14
157	Trifluridine/tipiracil plus bevacizumab as a firstâ€line treatment for elderly patients with metastatic colorectal cancer (KSCC1602): A multicenter phase II trial. Cancer Medicine, 2021, 10, 454-461.	2.8	14
158	Expression of CD44 variant 9 induces chemoresistance of gastric cancer by controlling intracellular reactive oxygen spices accumulation. Gastric Cancer, 2021, 24, 1089-1099.	5.3	14
159	Clinical significance of adjuvant surgery following chemotherapy for patients with initially unresectable stage IV gastric cancer. Anticancer Research, 2015, 35, 401-6.	1.1	14
160	Expression of the anaphylatoxin C5a receptor in gastric cancer: implications for vascular invasion and patient outcomes. Medical Oncology, 2016, 33, 118.	2.5	13
161	Effect of EGFR and p-AKT Overexpression on Chromosomal Instability in Gastric Cancer. Annals of Surgical Oncology, 2016, 23, 1986-1992.	1.5	13
162	Rationale for and Design of the PARADIGM Study: Randomized Phase III Study of mFOLFOX6 Plus Bevacizumab or Panitumumab in Chemotherapy-naÃ¯ve Patients With RAS (KRAS/NRAS) Wild-type, Metastatic ColorectalÂCancer. Clinical Colorectal Cancer, 2017, 16, 158-163.	2.3	13

#	Article	IF	Citations
163	Rationale and design of the TRUSTY study: a randomised, multicentre, open-label phase II/III study of trifluridine/tipiracil plus bevacizumab versus irinotecan, fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer progressive during or following first-line oxaliplatin-based chemotherapy. ESMO Open, 2018, 3, e000411.	4.5	13
164	Cytotoxicity of trifluridine correlates with the thymidine kinase 1 expression level. Scientific Reports, 2019, 9, 7964.	3.3	13
165	Prognostic scores for evaluating the survival benefit of regorafenib or trifluridine/tipiracil in patients with metastatic colorectal cancer: an exploratory analysis of the REGOTAS study. International Journal of Clinical Oncology, 2020, 25, 614-621.	2.2	13
166	Multicenter phase II study of SOX plus trastuzumab for patients with HER2+ metastatic or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS 1501B. Cancer Chemotherapy and Pharmacology, 2020, 85, 217-223.	2.3	13
167	Potential association of LOXL1 with peritoneal dissemination in gastric cancer possibly via promotion of EMT. PLoS ONE, 2020, 15, e0241140.	2.5	13
168	Changes in expression levels of ERCC1, DPYD, and VEGFA mRNA after first-line chemotherapy of metastatic colorectal cancer: results of a multicenter study. Oncotarget, 2015, 6, 34004-34013.	1.8	13
169	High-resolution fluorescent analysis of microsatellite instability in gastric cancer. European Journal of Gastroenterology and Hepatology, 2007, 19, 701-709.	1.6	12
170	Transient Elastography for the Prediction of Oxaliplatin-Associated Liver Injury in Colon Cancer Patients : A Preliminary Analysis. Journal of Gastrointestinal Cancer, 2008, 39, 82-85.	1.3	12
171	Book-Binding Technique for Billroth I Anastomosis During Totally Laparoscopic Distal Gastrectomy. Journal of the American College of Surgeons, 2014, 219, e69-e73.	0.5	12
172	Chemotherapy-induced nausea and vomiting (CINV) in 190 colorectal cancer patients: a prospective registration study by the CINV study group of Japan. Expert Opinion on Pharmacotherapy, 2017, 18, 753-758.	1.8	12
173	Clinical significance of ZNF750 gene expression, a novel tumor suppressor gene, in esophageal squamous cell carcinoma. Oncology Letters, 2017, 14, 1795-1801.	1.8	12
174	A novel histological examination with dynamic threeâ€dimensional reconstruction from multiple immunohistochemically stained sections of a <scp>PD</scp>â€L1â€positive colon cancer. Histopathology, 2018, 72, 697-703.	2.9	12
175	Thymidine Kinase 1 Loss Confers Trifluridine Resistance without Affecting 5-Fluorouracil Metabolism and Cytotoxicity. Molecular Cancer Research, 2018, 16, 1483-1490.	3.4	12
176	Efficacy of Novel Multispectral Imaging DeviceÂtoÂDetermine Anastomosis for Esophagogastrostomy. Journal of Surgical Research, 2019, 242, 11-22.	1.6	12
177	Recent developments in cancer research: Expectations for a new remedy. Annals of Gastroenterological Surgery, 2021, 5, 419-426.	2.4	12
178	Cancer-derived cholesterol sulfate is a key mediator to prevent tumor infiltration by effector T cells. International Immunology, 2022, 34, 277-289.	4.0	12
179	Acute Liver Failure Due to Regorafenib May Be Caused by Impaired Liver Blood Flow: A Case Report. Anticancer Research, 2015, 35, 4037-41.	1.1	12
180	Final Analysis of 3 Versus 6 Months of Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy in Patients With Stage III Colon Cancer: The Randomized Phase III ACHIEVE Trial. Journal of Clinical Oncology, 2022, 40, 3419-3429.	1.6	12

#	Article	IF	Citations
181	Loss of Heterozygosity at BRCA1 Locus Is Significantly Associated with Aggressiveness and Poor Prognosis in Breast Cancer. Annals of Surgical Oncology, 2012, 19, 1499-1507.	1.5	11
182	Contribution of BubR1 to oxidative stressâ€induced aneuploidy in p53â€deficient cells. Cancer Medicine, 2013, 2, 447-456.	2.8	11
183	Clinical Significance of SIP1 and E-cadherin in Patients with Esophageal Squamous Cell Carcinoma. Annals of Surgical Oncology, 2015, 22, 2608-2614.	1.5	11
184	Reduced MUTYH, MTH1, and OGG1 expression and TP53 mutation in diffuse-type adenocarcinoma of gastric cardia. Human Pathology, 2016, 52, 145-152.	2.0	11
185	Exploration of potential prognostic biomarkers in aflibercept plus <scp>FOLFIRI</scp> in Japanese patients with metastatic colorectal cancer. Cancer Science, 2019, 110, 3565-3572.	3.9	11
186	Impact of a metastatic site on circulating tumor DNA (ctDNA) analysis in patients (pts) with metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2021, 39, 3554-3554.	1.6	11
187	Intratumoral lymphangiogenesis and prognostic significance of VEGFC expression in gastric cancer. Anticancer Research, 2014, 34, 3911-5.	1.1	11
188	Significance of accurate human epidermal growth factor receptor-2 (HER2) evaluation as a new biomarker in gastric cancer. Anticancer Research, 2014, 34, 4207-12.	1.1	11
189	Pure laparoscopic rightâ€sided hepatectomy in the semiâ€prone position for synchronous colorectal cancer with liver metastases. Asian Journal of Endoscopic Surgery, 2014, 7, 133-137.	0.9	10
190	A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC 0902). International Journal of Clinical Oncology, 2016, 21, 335-343.	2.2	10
191	Current status of and perspectives regarding neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma. Surgery Today, 2016, 46, 261-267.	1.5	10
192	Differences in PD-L1 expression on tumor and immune cells between lung metastases and corresponding primary tumors. Surgical Oncology, 2018, 27, 637-641.	1.6	10
193	DNA Replication Stress Induced by Trifluridine Determines Tumor Cell Fate According to p53 Status. Molecular Cancer Research, 2020, 18, 1354-1366.	3.4	10
194	Phase II study of S-1 and oxaliplatin as neoadjuvant chemotherapy for locally advanced adenocarcinoma of the gastric or esophagogastric junction: KSCC1601. Gastric Cancer, 2022, 25, 180-187.	5.3	10
195	Oxysterol binding protein-like 3 (OSBPL3) is a novel driver gene that promotes tumor growth in part through R-Ras/Akt signaling in gastric cancer. Scientific Reports, 2021, 11, 19178.	3.3	10
196	Checkpoint with forkhead-associated and ring finger promoter hypermethylation correlates with microsatellite instability in gastric cancer. World Journal of Gastroenterology, 2009, 15, 2520.	3.3	10
197	Hyperthermia combined with chemotherapy for patients with residual or recurrent oesophageal cancer after definitive chemoradiotherapy. Anticancer Research, 2015, 35, 2299-303.	1.1	10
198	Clinical significance of cytokeratin positive cells in bone marrow of gastric cancer patients. Journal of Cancer Research and Clinical Oncology, 2007, 133, 995-1000.	2.5	9

#	Article	IF	Citations
199	Successful treatment of tracheomediastinal fistula after tracheal injury obtained during esophagectomy using the pectoralis major muscle: a case report. Esophagus, 2008, 5, 41-44.	1.9	9
200	The impact of a high-frequency microsatellite instability phenotype on the tumor location-related genetic differences in colorectal cancer. Cancer Genetics and Cytogenetics, 2010, 196, 133-139.	1.0	9
201	Recent advances in multidisciplinary approach for rectal cancer. International Journal of Clinical Oncology, 2015, 20, 641-649.	2.2	9
202	Clinical Significance of Totally Laparoscopic Distal Gastrectomy: A Comparison of Short-term Outcomes Relative to Open and Laparoscopic-assisted Distal Gastrectomy. Surgical Laparoscopy, Endoscopy and Percutaneous Techniques, 2016, 26, 372-376.	0.8	9
203	Primary amelanotic malignant melanoma of the esophagus: a case report. Surgical Case Reports, 2019, 5, 4.	0.6	9
204	CTDSP1 inhibitor rabeprazole regulates DNA-PKcs dependent topoisomerase I degradation and irinotecan drug resistance in colorectal cancer. PLoS ONE, 2020, 15, e0228002.	2.5	9
205	Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer. BMC Cancer, 2020, 20, 687.	2.6	9
206	Gastric glomus tumor with a preoperative diagnosis by endoscopic ultrasonography-guided fine needle aspiration: a case report. International Cancer Conference Journal, 2021, 10, 35-40.	0.5	9
207	Histological categorisation of the desmoplastic reaction is a predictor of patient prognosis in oesophageal squamous cell carcinoma. Histopathology, 2021, 79, 219-226.	2.9	9
208	Sustainable Clinical Development of Adjuvant Chemotherapy for Colon Cancer. Annals of Gastroenterological Surgery, 2022, 6, 37-45.	2.4	9
209	Cancer-associated Fibroblast-derived Spondin-2 Promotes Motility of Gastric Cancer Cells. Cancer Genomics and Proteomics, 2021, 18, 521-529.	2.0	9
210	Capecitabine reverses tumor escape from anti-VEGF through the eliminating CD11bhigh/Gr1high myeloid cells. Oncotarget, 2018, 9, 17620-17630.	1.8	9
211	Induction of potentially lethal hypermagnesemia, ischemic colitis, and toxic megacolon by a preoperative mechanical bowel preparation: report of a case. Surgical Case Reports, 2016, 2, 18.	0.6	8
212	Monitoring trifluridine incorporation in the peripheral blood mononuclear cells of colorectal cancer patients under trifluridine/tipiracil medication. Scientific Reports, 2017, 7, 16969.	3.3	8
213	Changes in HER2 Expression and Amplification Status Following Preoperative Chemotherapy for Gastric Cancer. In Vivo, 2018, 32, 1491-1498.	1.3	8
214	Principles and development of collagen-mediated tissue fusion induced by laser irradiation. Scientific Reports, 2019, 9, 9383.	3.3	8
215	The balance of forces generated by kinesins controls spindle polarity and chromosomal heterogeneity in tetraploid cells. Journal of Cell Science, 2019, 132, .	2.0	8
216	A Validation Study for Recurrence Risk Stratification of Stage II Colon Cancer Using the 55-Gene Classifier. Oncology, 2020, 98, 534-541.	1.9	8

#	Article	IF	Citations
217	FMSâ€like tyrosine kinase 3 (FLT3) amplification in patients with metastatic colorectal cancer. Cancer Science, 2021, 112, 314-322.	3.9	8
218	Randomized phase II study comparing the efficacy and safety of SOX versus mFOLFOX6 as neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer (KSCC1301). BMC Cancer, 2021, 21, 23.	2.6	8
219	Clinical impact of the tripleâ€layered circular stapler for reducing the anastomotic leakage in rectal cancer surgery: Porcine model and multicenter retrospective cohort analysis. Annals of Gastroenterological Surgery, 2022, 6, 256-264.	2.4	8
220	Low Visceral Fat Content Is a Negative Predictive Marker for Bevacizumab in Metastatic Colorectal Cancer. Anticancer Research, 2018, 38, 491-499.	1.1	8
221	Conversion to Neuroendocrine Carcinoma from Squamous Cell Carcinoma of the Esophagus After Definitive Chemoradiotherapy. Anticancer Research, 2016, 36, 4045-9.	1.1	8
222	Clinical Validity of Plasma-Based Genotyping for Microsatellite Instability Assessment in Advanced GI Cancers: SCRUM-Japan GOZILA Substudy. JCO Precision Oncology, 2022, 6, e2100383.	3.0	8
223	Impact of the suboptimal communication network environment on telerobotic surgery performance and surgeon fatigue. PLoS ONE, 2022, 17, e0270039.	2.5	8
224	The Use of a Circular Side Stapling Technique in Laparoscopic Low Anterior Resection for Rectal Cancer: Experience of 30 Serial Cases. International Surgery, 2015, 100, 979-983.	0.1	7
225	Loss of Heterozygosity of PTEN (Encoding Phosphate and Tensin Homolog) Associated with Elevated HER2 Expression Is an Adverse Prognostic Indicator in Gastric Cancer. Oncology, 2015, 88, 189-194.	1.9	7
226	Biological and clinical significance of loss of heterozygosity at the INPP4B gene locus in Japanese breast cancer. Breast, 2016, 25, 62-68.	2.2	7
227	S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102). International Journal of Clinical Oncology, 2016, 21, 705-712.	2.2	7
228	Anal metastasis of rectal cancerâ€"adenocarcinoma of squamous cells: a case report and literature review. Surgical Case Reports, 2017, 3, 55.	0.6	7
229	The evolution of surgical treatment for gastrointestinal cancers. International Journal of Clinical Oncology, 2019, 24, 1333-1349.	2.2	7
230	Sarcopenia discriminates poor prognosis in elderly patients following emergency surgery for perforation panperitonitis. Annals of Gastroenterological Surgery, 2019, 3, 630-637.	2.4	7
231	RAD51 Expression as a Biomarker to Predict Efficacy of Preoperative Therapy and Survival for Esophageal Squamous Cell Carcinoma. Annals of Surgery, 2020, Publish Ahead of Print, .	4.2	7
232	Real-World Evidence on Second-Line Treatment of Metastatic Colorectal Cancer Using Fluoropyrimidine, Irinotecan, and Angiogenesis Inhibitor. Clinical Colorectal Cancer, 2021, 20, e173-e184.	2.3	7
233	APOLLON: A phase I/II study of panitumumab combined with TAS-102 in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2018, 36, 3523-3523.	1.6	7
234	Phase I study of S-1 and biweekly docetaxel combination chemotherapy for advanced and recurrent gastric cancer. Oncology Reports, 2006, 15, 849-54.	2.6	7

#	Article	IF	Citations
235	Suppression of MAL gene expression in gastric cancer correlates with metastasis and mortality. Fukuoka Acta Medica, 2013, 104, 344-9.	0.1	7
236	Intensive Immunofluorescence Staining Methods for Low Expression Protein: Detection of Intestinal Stem Cell Marker LGR5. Acta Histochemica Et Cytochemica, 2015, 48, 159-164.	1.6	6
237	A prospective study of XELIRI plus bevacizumab as a first-line therapy in Japanese patients with unresectable or recurrent colorectal cancer (KSCC1101). International Journal of Clinical Oncology, 2017, 22, 913-920.	2.2	6
238	Gastric cancer with synchronous and metachronous hepatic metastasis predicted by enhancement pattern on multiphasic contrast-enhanced CT. European Journal of Radiology, 2018, 108, 165-171.	2.6	6
239	Short- and Long-term Outcomes of Surgical Treatment for Remnant Gastric Cancer After Distal Gastrectomy. Anticancer Research, 2019, 39, 1411-1415.	1.1	6
240	Detection of trifluridine in tumors of patients with metastatic colorectal cancer treated with trifluridine/tipiracil. Cancer Chemotherapy and Pharmacology, 2020, 85, 1029-1038.	2.3	6
241	PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer.. Journal of Clinical Oncology, 2021, 39, 85-85.	1.6	6
242	The effects of <scp>ARID1A</scp> mutations on colorectal cancer and associations with <scp>PDâ€Ł1</scp> expression by stromal cells. Cancer Reports, 2022, 5, e1420.	1.4	6
243	Extended total gastrectomy after nivolumab for unresectable multivisceral invasive gastric cancer. Surgical Case Reports, 2020, 6, 298.	0.6	6
244	DENEB: Development of new criteria for curability after local excision of pathological T1 colorectal cancer using liquid biopsy. Cancer Science, 2022, 113, 1531-1534.	3.9	6
245	Assessment of surgical treatment and postoperative nutrition in gastric cancer patients older than 80 years. Anticancer Research, 2015, 35, 511-5.	1.1	6
246	Phase II Trial of Alternating mFOLFOX6 and FOLFIRI Regimens in the First-Line Treatment for Unresectable or Metastatic Colorectal Cancer (KSCC0701). Oncology, 2013, 84, 233-239.	1.9	5
247	Multicenter phase II study of combination therapy with cetuximab and S-1 in patients with KRAS exon 2 wild-type unresectable colorectal cancer previously treated with irinotecan, oxaliplatin, and fluoropyrimidines (KSCC 0901 study). Cancer Chemotherapy and Pharmacology, 2016, 78, 585-593.	2.3	5
248	Prophylactic Effect of Dexamethasone on Regorafenib-Related Fatigue and/or Malaise: A Randomized, Placebo-Controlled, Double-Blind Clinical Study in Patients with Unresectable Metastatic Colorectal Cancer (KSCC1402/HGCSG1402). Oncology, 2018, 94, 289-296.	1.9	5
249	Clinical Significance of the Wild Type p53-Induced Phosphatase 1 Expression in Invasive Breast Cancer. Clinical Breast Cancer, 2018, 18, e643-e650.	2.4	5
250	â€œEnergy-less techniqueâ€•with mini-clips for recurrent laryngeal nerve lymph node dissection in prone thoracoscopic esophagectomy for esophageal cancer. American Journal of Surgery, 2018, 216, 1212-1214.	1.8	5
251	BUBR1 Insufficiency Is Correlated with eNOS Reduction Experimentally In Vitro and In Vivo, and in Gastric Cancer Tissue. Anticancer Research, 2018, 38, 6099-6106.	1.1	5
252	Changing the Dissectable Layer: Novel Thoracoscopic Esophagectomy Method for Lymphadenectomy along the Left Recurrent Laryngeal Nerve. Journal of the American College of Surgeons, 2020, 230, e1-e6.	0.5	5

#	Article	IF	Citations
253	Autocrine Leukemia Inhibitory Factor Promotes Esophageal Squamous Cell Carcinoma Progression via Src Family Kinase-Dependent Yes-Associated Protein Activation. Molecular Cancer Research, 2020, 18, 1876-1888.	3.4	5
254	Minimal residual disease by circulating tumor DNA analysis for colorectal cancer patients receiving radical surgery: An initial report from CIRCULATE-Japan.. Journal of Clinical Oncology, 2021, 39, 3608-3608.	1.6	5
255	REVERCE: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecanâ€"Biomarker analysis.. Journal of Clinical Oncology, 2018, 36, 3510-3510.	1.6	5
256	Trifluridine/tipiracil plus bevacizumab in elderly patients with previously untreated metastatic colorectal cancer (KSCC1602): A multicenter, phase II clinical trial.. Journal of Clinical Oncology, 2019, 37, 3548-3548.	1.6	5
257	The Clinical Usefulness of the LigaSureâ„¢ Small Jaw in Axillary Lymph Node Dissection in Patients with Breast Cancer. Anticancer Research, 2018, 38, 2359-2362.	1.1	5
258	Staged operation for synchronous quintuple cancer in the oral cavity, hypopharynx, and esophagus. Esophagus, 2012, 9, 228-233.	1.9	4
259	Simultaneous resection of colorectal cancer and liver metastases in the right lobe using pure laparoscopic surgery. Surgery Today, 2014, 44, 1588-1592.	1.5	4
260	Esophageal cancer associated with bilateral hilar lymphadenopathy caused by sarcoid-like reactions: a report of two cases. Esophagus, 2015, 12, 322-326.	1.9	4
261	Development of fistula between esophagogastric anastomotic site and cartilage portion of trachea after subtotal esophagectomy for cervical esophageal cancer: a case report. Surgical Case Reports, 2016, 2, 107.	0.6	4
262	Real-Time Accurate Identification of Tumor Site Using a Mobile X-Ray Image-Intensifier System During Laparoscopic Gastrectomy. Journal of the American College of Surgeons, 2016, 222, e1-e7.	0.5	4
263	Phase II trial of capecitabine plus modified cisplatin (mXP) as first-line therapy in Japanese patients with metastatic gastric cancer (KSCC1104). Cancer Chemotherapy and Pharmacology, 2017, 79, 147-153.	2.3	4
264	Recurrence with pagetoid spread arising 17Âyears after surgery for intramucosal rectal cancer: a case report. Surgical Case Reports, 2017, 3, 85.	0.6	4
265	Developing a Phosphospecific IHC Assay as a Predictive Biomarker for Topoisomerase I Inhibitors. Journal of Histochemistry and Cytochemistry, 2018, 66, 549-561.	2.5	4
266	Non-familial juvenile polyposis of the stomach with gastric cancers: a case report. Surgical Case Reports, 2018, 4, 79.	0.6	4
267	Intestinal BehÃ§etâ€™s Disease with Primary Myelofibrosis Involving Trisomy 8. Acta Haematologica, 2019, 142, 253-256.	1.4	4
268	CT gastrography â€œwall-carving techniqueâ€•of gastric cancer: impact of contrast enhancement based on layer depth. Japanese Journal of Radiology, 2019, 37, 597-604.	2.4	4
269	Factors of incomplete colonoscopy for stenosing colorectal cancer: CT colonography features. Japanese Journal of Radiology, 2020, 38, 973-978.	2.4	4
270	Identification of characteristic compounds of moderate volatility in breast cancer cell lines. PLoS ONE, 2020, 15, e0235442.	2.5	4

#	Article	IF	Citations
271	Immunogenic characteristics of microsatellite instabilityâ€low esophagogastric junction adenocarcinoma based on clinicopathological, molecular, immunological and survival analyses. International Journal of Cancer, 2021, 148, 1260-1275.	5.1	4
272	Mutational signatures in squamous cell carcinoma of the lung. Journal of Thoracic Disease, 2021, 13, 1075-1082.	1.4	4
273	Efficacy of pembrolizumab in microsatellite instability-high locally advanced cholangiocarcinoma: a case report. Clinical Journal of Gastroenterology, 2021, 14, 1459-1463.	0.8	4
274	Clinical outcomes of surgical resection for recurrent lesion after curative esophagectomy for esophageal squamous cell carcinoma: a nationwide, large-scale retrospective study. Esophagus, 2022, 19, 57-68.	1.9	4
275	Multicenter observational study on re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab.. Journal of Clinical Oncology, 2018, 36, 4038-4038.	1.6	4
276	Chemoradiotherapy for Solitary Skeletal Muscle Metastasis from Oesophageal Cancer: Case Report and Brief Literature Review. , 2017, 37, 5687-5691.		4
277	Tumor progression by epithelial-mesenchymal transition in ARID1A- and SMARCA4-aberrant solid-type poorly differentiated gastric adenocarcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 1063-1075.	2.8	4
278	Impact of postoperative integrated genomic and epigenomic signatures of circulating tumor DNA (ctDNA) on recurrence in resected colorectal cancer: Initial report of a prospective ctDNA monitoring study COSMOS-CRC-01.. Journal of Clinical Oncology, 2022, 40, 168-168.	1.6	4
279	Case of early adenosquamous carcinoma of the stomach. Fukuoka Acta Medica, 2013, 104, 315-20.	0.1	4
280	Significance of stroke volume variation during hepatic resection under infrahepatic inferior vena cava and portal triad clamping. Fukuoka Acta Medica, 2013, 104, 362-9.	0.1	4
281	Laparoscopic Total Gastrectomy for RGC: Four Case Reports. Anticancer Research, 2015, 35, 5023-6.	1.1	4
282	CD44v3,8â€10 is essential for Slugâ€dependent vimentin gene expression to acquire TGFâ€Î²1â€induced tumor cell motility. Cancer Science, 2022, 113, 2654-2667.	3.9	4
283	Phase II trial of an alternating regimen consisting of first-line mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: FIREFOX plus bevacizumab trial (KSCC0801). International Journal of Clinical Oncology, 2016, 21, 110-117.	2.2	3
284	New Anastomosis Technique to Prevent Anastomotic Leakage in Laparoscopic Anterior Resection for Rectal Cancer, Especially Upper Rectal Cancer. In Vivo, 2020, 34, 3533-3538.	1.3	3
285	Reintroduction of nivolumab in a patient with gastric cancer after improvement of nivolumab-induced acute interstitial nephritis: a case report. International Cancer Conference Journal, 2020, 9, 127-132.	0.5	3
286	Efficacy and feasibility of S-1 plus oxaliplatin (C-SOX) for treating patients with stage III colon cancer (KSCC1303): final analysis of 3-year disease-free survival. International Journal of Clinical Oncology, 2020, 25, 1115-1122.	2.2	3
287	Characteristics of genomic alterations in circulating tumor DNA (ctDNA) in patients (Pts) with advanced gastrointestinal (GI) cancers in nationwide large-scale ctDNA screening:SCRUM-Japan Monstar-Screen.. Journal of Clinical Oncology, 2021, 39, 106-106.	1.6	3
288	Measurement of circumferential tumor extent of colorectal cancer on CT colonography: relation to clinicopathological features and patient prognosis after surgery. Japanese Journal of Radiology, 2021, 39, 966-972.	2.4	3

#	Article	IF	Citations
289	Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a firstâ€line treatment for metastatic colorectal cancer: Safety leadâ€in results from the QUATTRO-II study. Investigational New Drugs, 2021, 39, 1649-1655.	2.6	3
290	Infusion-related reaction to ramucirumab plus FOLFIRI in patients with advanced colorectal cancer. International Journal of Clinical Oncology, 2021, 26, 2025-2028.	2.2	3
291	Significance of the vimentin expression in triple-negative breast cancer.. Journal of Clinical Oncology, 2013, 31, 1056-1056.	1.6	3
292	Genomic alterations after EGFR blockade in patients with RAS wild-type metastatic colorectal cancer: Combined tissue and blood-based analysis from SCRUM-Japan GI-SCREEN and GOZILA.. Journal of Clinical Oncology, 2019, 37, 3528-3528.	1.6	3
293	A randomized, double-blind, phase III study comparing trifluridine/tipiracil hydrochloride therapy versus placebo in resected colorectal cancer patients who are positive for blood circulating tumor DNA after standard adjuvant therapy (EPOC 1905): ALTAIR trial in CIRCULATE-Japan (trial in progress).. Journal of Clinical Oncology, 2022, 40, TPS215-TPS215.	1.6	3
294	Application of splenectomy to decompress portal pressure in left lobe living donor liver transplantation. Fukuoka Acta Medica, 2013, 104, 282-9.	0.1	3
295	Total laparoscopic distal gastrectomy for elderly patients with gastric cancer. Fukuoka Acta Medica, 2013, 104, 290-8.	0.1	3
296	Minimally invasive total pharyng-laryngo-esophagectomy and reconstruction with gastric tube: report of three cases. Fukuoka Acta Medica, 2013, 104, 442-8.	0.1	3
297	Cardiac tamponade due to bleeding as a potential lethal complication after surgery for esophageal cancer. Anticancer Research, 2015, 35, 407-11.	1.1	3
298	Laparoscopic Gastrectomy for Gastric Cancer with Peritoneal Dissemination after Induction Chemotherapy. Case Reports in Gastroenterology, 2013, 7, 516-521.	0.6	2
299	Diagnosis of early colorectal cancer invasion depth by quantitative evaluation of the basal indentation in CT colonography. Japanese Journal of Radiology, 2016, 34, 786-794.	2.4	2
300	Distant lymph node metastases caused by esophageal cancer invasion to the lamina propria: a case report. Surgical Case Reports, 2016, 2, 143.	0.6	2
301	Final report of KSCC0803: feasibility study of capecitabine as adjuvant chemotherapy for stage III colon cancer in Japan. International Journal of Clinical Oncology, 2017, 22, 505-510.	2.2	2
302	Effect of age factors on health-related quality of life in patients with lower rectal cancer after sphincter-saving surgery: A 1-year longitudinal study. Archives of Gerontology and Geriatrics, 2018, 79, 185-191.	3.0	2
303	Protocol of the EFFORT study: a prospective study of FOLFIRI plus aflibercept as second-line treatment after progression on FOLFOXIRI plus bevacizumab or during maintenance treatment in patients with unresectable/metastatic colorectal cancer. BMC Cancer, 2020, 20, 1116.	2.6	2
304	A phase I/II study of S-1 and irinotecan (IRIS) combined with cetuximab in patients with RAS wild-type metastatic colorectal cancer (KSCC1401). Cancer Chemotherapy and Pharmacology, 2020, 86, 285-294.	2.3	2
305	Thoracoscopic esophagectomy in total pharyngolaryngoesophagectomy for esophageal cancer; A case series. Annals of Medicine and Surgery, 2020, 60, 9-13.	1.1	2
306	Continuous formation of small clusters with LGR5-positive cells contributes to tumor growth in a colorectal cancer xenograft model. Laboratory Investigation, 2021, 101, 12-25.	3.7	2

#	Article	IF	Citations
307	Multicohort Retrospective Validation of a Predictive Biomarker for Topoisomerase I Inhibitors. Clinical Colorectal Cancer, 2021, 20, e129-e138.	2.3	2
308	Indications for laparoscopic surgery for older rectal cancer patients with comorbidities. Surgery Today, 2021, 51, 721-726.	1.5	2
309	ASO Author Reflection: Radiomics-Based Prediction for the Responder to First-Line Oxaliplatin-Based Chemotherapy in Patients with Colorectal Liver Metastasis. Annals of Surgical Oncology, 2021, 28, 2986-2987.	1.5	2
310	Feasibility of hepatic resection for liver metastasis of head-and-neck carcinoma or esophageal carcinoma: a multi-center experience. Surgery Today, 2021, 51, 1932-1937.	1.5	2
311	Monitoring FTD in the peripheral blood mononuclear cells of elderly patients with metastatic colorectal cancer administered FTD plus bevacizumab as firstâ€line treatment. Cancer Science, 2021, 112, 2436-2441.	3.9	2
312	Liver resectability following S-1+L-OHP with cetuximab as the first-line treatment of unresectable liver limited metastases from KRAS exon 2 wild-colorectal cancer in Japanese patients (KSCC 1002).. Journal of Clinical Oncology, 2015, 33, 755-755.	1.6	2
313	Differential expression of insulin-like growth factor 1 in human primary liver cancer. Fukuoka Acta Medica, 2013, 104, 334-8.	0.1	2
314	Living donor liver transplantation followed by total gastrectomy--a two-stage planed operative strategy for early gastric cancer concomitant with decompensated liver cirrhosis. Anticancer Research, 2014, 34, 4307-10.	1.1	2
315	One-stage Procedure for Concomitant Abdominal Aortic Aneurysm and Gastric Cancer. Anticancer Research, 2015, 35, 6909-12.	1.1	2
316	Threeâ€dimensional imaging of intramural perineural invasion in colorectal cancer: Threeâ€dimensional reconstruction approach with multiple immunohistochemically stained sections. Pathology International, 2022, 72, 293-299.	1.3	2
317	A phase II multicenter trial assessing the efficacy and safety of first-line S-1 + ramucirumab in elderly patients with advanced/recurrent gastric cancer: KSCC1701. European Journal of Cancer, 2022, 166, 279-286.	2.8	2
318	Evaluation of a 55-gene classifier as a prognostic biomarker for adjuvant chemotherapy in stage III colon cancer patients. BMC Cancer, 2021, 21, 1332.	2.6	2
319	The realâ€world data on microsatellite instability status in various unresectable or metastatic solid tumors. Cancer Science, 2021, , .	3.9	2
320	Long-term treatment with panitumumab monotherapy for recurrent colorectal cancer. International Cancer Conference Journal, 2015, 4, 151-154.	0.5	1
321	Mixed spindle and epithelioid cell type gastrointestinal stromal tumor of the esophagus: a case report. Esophagus, 2016, 13, 301-305.	1.9	1
322	Successful surgical intervention for rectal perforation due to polyarteritis nodosa: report of a case. Surgical Case Reports, 2017, 3, 43.	0.6	1
323	Study protocol of a phase II clinical trial (KSCC1501A) examining oxaliplatinâ€‰+â€‰S-1 for treatment of HER2-negative advanced/recurrent gastric cancer previously untreated with chemotherapy. BMC Cancer, 2018, 18, 57.	2.6	1
324	Successful multidisciplinary treatment including repeated metastasectomy for recurrent squamous cell esophageal carcinoma: a case report. Surgical Case Reports, 2019, 5, 72.	0.6	1

#	Article	IF	Citations
325	Primary anorectal malignant melanoma with laparoscopic abdominoperineal resection: a case study and review of the relevant literature. International Cancer Conference Journal, 2020, 9, 116-122.	0.5	1
326	Quadruple gastrointestinal cancer with discordance of mismatch repair protein deficiency and microsatellite instability suggesting Lynch syndrome. International Cancer Conference Journal, 2021, 10, 2-5.	0.5	1
327	Safety and efficacy of S-1 plus oxaliplatin 130Âmg/m2 combination therapy in patients with previously untreated HER2-negative unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: a phase II trial (KSCC1501A). International Journal of Clinical Oncology, 2021, 26, 345-354.	2.2	1
328	Late recurrence of cancer stem cell-positive colorectal cancer liver metastases after 15Âyears. Clinical Journal of Gastroenterology, 2021, 14, 613-616.	0.8	1
329	Overexpression of the MTA1 gene in gastrointestinal carcinomas: Correlation with invasion and metastasis. International Journal of Cancer, 1997, 74, 459-463.	5.1	1
330	A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC).. Journal of Clinical Oncology, 2015, 33, 3515-3515.	1.6	1
331	A validation study of stratification by the 55-gene classifier for assessing recurrence risk in stage II colon cancer: The 55 STAR study (UMIN23879).. Journal of Clinical Oncology, 2018, 36, 3526-3526.	1.6	1
332	Retrospective multicenter study for assessment of association between imaging change and outcome after treatment of regorafenib: KSCC1603.. Journal of Clinical Oncology, 2019, 37, 509-509.	1.6	1
333	Identification of site-specific genome alterations in metastatic colorectal cancer: Sub-study 003 of the SCRUM-Japan GI-SCREEN.. Journal of Clinical Oncology, 2019, 37, 578-578.	1.6	1
334	Phase I/II study of panitumumab (PANI) combined with trifluridine/tipiracil (FTD/TPI) in patients (pts) with previously treated RAS wild-type (wt) metastatic colorectal cancer (mCRC): Final results of APOLLON study.. Journal of Clinical Oncology, 2019, 37, 624-624.	1.6	1
335	Significance of multimodality therapy for esophageal cancer synchronously or metachronously associated with head and neck cancer.. Journal of Clinical Oncology, 2013, 31, 132-132.	1.6	1
336	Two Cases of Advanced Gastric Cancer Showing Multiple Liver Metastases Diagnosed with Paraneoplastic Syndrome. Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons), 2014, 39, 900-905.	0.0	1
337	A Locally Advanced Breast Cancer that Achieved pCR with Pertuzumab, Trastuzumab and Docetaxel: Case Report. Anticancer Research, 2017, 37, 1917-1921.	1.1	1
338	The Local Recurrence of Breast Cancer with Squamous Metaplasia and Obvious Histological Heterogeneity. Anticancer Research, 2017, 37, 5249-5254.	1.1	1
339	Gastric Cancer of "Crawling Type" Detected by Additional Gastrectomy After Endoscopic Submucosal Resection. Anticancer Research, 2018, 38, 2335-2338.	1.1	1
340	Predictive factors for early mortality after initiation of regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer.. Journal of Clinical Oncology, 2019, 37, 3560-3560.	1.6	1
341	Exploratory analysis of baseline tumor burden in the TRUSTY study: A randomized phase 2/3 study of trifluridine/tipiracil plus bevacizumab versus irinotecan and fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer.. Journal of Clinical Oncology, 2022, 40, 87-87.	1.6	1
342	Geriatric-8 (G8) screening tool stratified the efficacy of S-1 plus ramucirumab in elderly patients with advanced/recurrent gastric cancer: A post-hoc analysis of the KSCC1701 trial.. Journal of Clinical Oncology, 2022, 40, 256-256.	1.6	1

#	Article	IF	Citations
343	Plasma-informed minimal residual disease (MRD) assay: A multicenter prospective study in Japanese patients with stage II colorectal cancer.. Journal of Clinical Oncology, 2022, 40, 161-161.	1.6	1
344	Verification of our therapeutic criterion for acute cholecystitis: "perform a subemergency laparoscopic cholecystectomy when a patient is judged to be able to tolerate general anesthesia"--the experience in a single community hospital. Fukuoka Acta Medica, 2013, 104, 339-43.	0.1	1
345	Effect of CD133-positive stem cells in repeated recurrence of hepatocellular carcinoma after liver transplantation: a case report. Fukuoka Acta Medica, 2013, 104, 383-8.	0.1	1
346	Thoracoscopic pericardial drainage for gastric tube ulcer penetrated into the pericardium. Fukuoka Acta Medica, 2013, 104, 389-93.	0.1	1
347	Number of Lymph Node Metastases May Indicate the Regimen for Adjuvant Chemotherapy in Patients with Stage III Colorectal Cancer. Anticancer Research, 2015, 35, 6207-11.	1.1	1
348	Patient-specific meta-analysis of 12-gene colon cancer recurrence score validation studies for recurrence risk assessment after surgery with or without 5FU and oxaliplatin. Journal of Gastrointestinal Oncology, 2022, 13, 126-136.	1.4	1
349	Genomic Landscape of Primary Tumor Site and Clinical Outcome for Patients with Metastatic Colorectal Cancer Receiving Standard-of-Care Chemotherapy. Targeted Oncology, 2022, , 1.	3.6	1
350	Preoperative insertion of transanal ileus tubes for treatment of acute obstruction in cancer of the colon and rectum. Asia-Pacific Journal of Clinical Oncology, 2005, 1, 88-91.	1.1	0
351	Histological and biological characteristics of esophageal dysplasia. Esophagus, 2005, 2, 129-132.	1.9	0
352	Huge Gastric Carcinoma Showing an Exophytic Growth Pattern: A Case Report and Review of the Literature. Journal of Gastrointestinal Cancer, 2008, 39, 42-45.	1.3	0
353	Pharyngo-laryngo-esophagectomy and reconstruction with a gastric tube for corrosive pharyngoesophagitis. Esophagus, 2015, 12, 360-364.	1.9	0
354	Comparison of computed tomography imaging analyses for evaluation after chemotherapy in patients with colorectal cancer: a retrospective pooled analysis of six phase II clinical trials. International Journal of Clinical Oncology, 2019, 24, 1397-1405.	2.2	0
355	Obstructive rectal endometriosis treated by robot-assisted laparoscopic surgery: a case report. Surgical Case Reports, 2020, 6, 211.	0.6	0
356	A rare case of esophageal adenocarcinoma with urinary bladder metastasis. International Cancer Conference Journal, 2020, 9, 231-234.	0.5	0
357	Multicenter Cohort Study to Assess the Association between Changes on Imaging and Outcome after Regorafenib Treatment (KSCC1603). Oncology, 2020, 98, 719-726.	1.9	0
358	A multicenter phase II study of S-1 plus ramucirumab as first-line treatment in elderly patients with advanced/recurrent gastric cancer (KSCC1701).. Journal of Clinical Oncology, 2021, 39, 4043-4043.	1.6	0
359	Pre-treatment status of inflammation-based biomarkers in the patients with advanced gastric cancer who will be treated with nivolumab.. Journal of Clinical Oncology, 2021, 39, e16107-e16107.	1.6	0
360	Phase II study of combination therapy with S-1Âand cetuximab in patients with KRAS wild-type unresectable colorectal cancer who had previously received irinotecan, oxaliplatin, and fluoropyrimidines (KSCC0901).. Journal of Clinical Oncology, 2012, 30, 3558-3558.	1.6	0

#	Article	IF	Citations
361	Comparison of efficacy between irinotecan and paclitaxel monotherapy as second- or third-line chemotherapy after S-1 containing regimen for advanced or recurrent gastric cancer.. Journal of Clinical Oncology, 2012, 30, e14722-e14722.	1.6	0
362	PrognosticÂsignificance of KRAS and BRAF mutations in Japanese patients with colorectal cancer.. Journal of Clinical Oncology, 2012, 30, e14033-e14033.	1.6	0
363	Neoadjuvant chemoradiotherapy for potentially resectable esophageal squamous cell carcinoma and the significance of Rad51 expression as a factor predictive of the treatment response.. Journal of Clinical Oncology, 2012, 30, e14601-e14601.	1.6	0
364	Significance of accurate HER2 testing as a new biomarker in advanced gastric cancer.. Journal of Clinical Oncology, 2013, 31, 106-106.	1.6	0
365	A prospective study of XELOXÂplus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC0902).. Journal of Clinical Oncology, 2013, 31, 583-583.	1.6	0
366	Phase II study of docetaxel (DTX) and S-1 as neoadjuvant chemotherapy for potentially R0 advanced gastric cancer.. Journal of Clinical Oncology, 2013, 31, 74-74.	1.6	0
367	S-1/docetaxel compared with the other standard S-1 based regimens as a first-line chemotherapy for patients with advanced gastric cancer.. Journal of Clinical Oncology, 2013, 31, e15173-e15173.	1.6	0
368	A central review of resectability of optimally unresectable colorectal liver metastases following neoadjuvant chemotherapy (KSCC0802).. Journal of Clinical Oncology, 2013, 31, e14633-e14633.	1.6	0
369	TP53 mutation and BUBR1 overexpression characterize the DNA aneuploidy of gastric cancer.. Journal of Clinical Oncology, 2013, 31, e15039-e15039.	1.6	0
370	A Case of Curatively Resected Rectal Cancer with Liver Metastatis and Bladder Invasion Responding to IRIS+Câ^'mab. Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons), 2014, 39, 734-738.	0.0	0
371	Changes in expression levels of excision repair cross-complementing group 1 (ERCC1) and dihydropyrimidine dehydrogenase (DPD) after first-line oxaliplatin-based chemotherapy for metastatic colorectal cancer: Results of a multicenter study.. Journal of Clinical Oncology, 2014, 32, 463-463.	1.6	0
372	Relationship of global DNA hypomethylation-mediated chromosomal instability to the initiation and progression of esophageal squamous cell carcinoma.. Journal of Clinical Oncology, 2014, 32, e15011-e15011.	1.6	0
373	Trastuzumab plus chemotherapy based on the accurate HER2-positivity testing for patients with advanced gastric cancer.. Journal of Clinical Oncology, 2014, 32, e15075-e15075.	1.6	0
374	HER2 and programmed death-1 ligand-1 (PD-L1) expression in gastric carcinoma.. Journal of Clinical Oncology, 2014, 32, e15041-e15041.	1.6	0
375	Randomized phase II study of regorafenib followed by cetuximab versus reverse sequence for wild-type KRAS metastatic colorectal cancer previously treated with fluoropyrimidine, oxaliplatin, and irinotecan (REVERCE).. Journal of Clinical Oncology, 2014, 32, TPS3662-TPS3662.	1.6	0
376	Aberrations of BUBR1 expression and TP53 gene in human colorectal cancer.. Journal of Clinical Oncology, 2014, 32, e14578-e14578.	1.6	0
377	Rapidly Increased Peritoneal Metastases of Squamous Cell Carcinoma of the Upper Thoracic Esophagus after Preoperative Chemoradiotherapy—A Case Report—. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2015, 76, 2706-2711.	0.0	0
378	A prospective study of XELIRI plus bevacizumab as the first-line therapy in Japanese patients with unresectable or recurrent colorectal cancer (KSCC1101).. Journal of Clinical Oncology, 2015, 33, 752-752.	1.6	0

#	Article	IF	Citations
379	A prospective study of capecitabine plus modified cisplatin (mXP) as first-line therapy in Japanese patients with metastatic gastric cancer (KSCC1104).. Journal of Clinical Oncology, 2015, 33, 129-129.	1.6	0
380	Validation of postoperative adjuvant chemotherapy for elderly patients with stage II/III gastric cancer.. Journal of Clinical Oncology, 2015, 33, e15036-e15036.	1.6	0
381	A central review of liver resectability and pathological tumor response after chemotherapy in patients with initially unresectable colorectal cancer liver metastases: Phase II trials of mFOLFOX6 plus bevacizumab (KSCC0802), and SOX (S-1 and oxaliplatin) plus cetuximab (KSCC1002).. Journal of Clinical Oncology, 2015, 33, e14548-e14548.	1.6	0
382	Current Treatment and Application of Hyperthermia for Squamous Cell Carcinoma of the Esophagus. Thermal Medicine, 2017, 33, 63-73.	0.1	0
383	The clinical impact of the Prognostic Nutritional Index (PNI) and Controlling Nutritional Status (CONUT) score on breast cancer patients survival.. Journal of Clinical Oncology, 2017, 35, 1560-1560.	1.6	0
384	Patient reported outcomes (PRO) results for prophylactic effect of dexamethasone on regorafenib-related fatigue and/or malaise: a randomized, placebo-controlled, double-blind clinical study in patients with unresectable metastatic colorectal cancer: KSCC1402/HGCSG1402.. Journal of Clinical Oncology, 2018, 36, 10094-10094.	1.6	0
385	MSI-low is an intermediate type between MSI-high and MSS in esophagogastric junction adenocarcinoma.. Journal of Clinical Oncology, 2019, 37, 44-44.	1.6	0
386	Efficacy and safety of nivolumab monotherapy as the late line for patients with advanced gastric cancer in the real-world.. Journal of Clinical Oncology, 2019, 37, e14074-e14074.	1.6	0
387	Efficacy and safety of neoadjuvant chemotherapy for locally advanced gastric cancer in elderly patients: A phase II trial (KSCC1801).. Journal of Clinical Oncology, 2022, 40, 254-254.	1.6	0
388	Rendezvous technique treatment for late-onset biliary leakage after major hepatectomy of a living donor: report of a case. Fukuoka Acta Medica, 2013, 104, 309-14.	0.1	0
389	Recurrent hepatitis B following recurrence of hepatocellular carcinoma after living donor liver transplantation. Fukuoka Acta Medica, 2013, 104, 376-82.	0.1	0
390	Laparoscopic Resection of Gastric Cancer in a Patient with Chronic Lymphocytic Leukemia Accompanied by Neutropenia. Anticancer Research, 2016, 36, 1779-83.	1.1	0
391	Influence of Robotic Rectal Resection Versus Laparoscopic Rectal Resection on Postoperative Ileus: A Single-center Experience. Surgical Laparoscopy, Endoscopy and Percutaneous Techniques, 2022, Publish Ahead of Print, .	0.8	0
392	Title is missing!. , 2020, 15, e0228002.		0
393	Title is missing!. , 2020, 15, e0228002.		0
394	Title is missing!. , 2020, 15, e0228002.		0
395	Title is missing!. , 2020, 15, e0228002.		0
396	Title is missing!. , 2020, 15, e0228002.		0

#	Article	IF	Citations
397	Title is missing!. , 2020, 15, e0228002.		0
398	Clinical impact of MAPK pathway alterations in advanced biliary tract cancer (BTC): SCRUM-Japan GOZILA and COLOMATE international collaboration.. Journal of Clinical Oncology, 2022, 40, 4086-4086.	1.6	0
399	VOYAGER (KSCC1902): A single-arm, multicenter, phase II study of early induction of nivolumab during second-line treatment with taxane Â± ramucirumab for advanced gastric or gastro-esophageal junction cancer.. Journal of Clinical Oncology, 2022, 40, 4028-4028.	1.6	0